Family Med

Your Article Summary

See Latest Articles

A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women
Psychoneuroendocrinology, 07/01/09

Tierney MC et al. - These results suggest that benefits of estrogen exposure may be limited to those with average to above average scores on the delayed verbal recall. HT dose and formulation may have contributed to these beneficial outcomes. Replication is warranted before recommendations can be made in the clinical setting.

• 2-year, randomized, double-blind, placebo-controlled trial of 142 women aged 61–87, randomly assigned to receive 1 mg 17-β estradiol daily and 0.35 mg norethindrone 3 days/week or daily placebo for 2 years.
• The primary outcome was short-delay verbal recall of the California Verbal Learning Test (CVLT).
• To look for differences in response to HT by baseline short-delay recall, this study examined the primary outcome in participants grouped according to whether their baseline scores were below average for the age group or greater than or equal to this score and according to whether they met criteria for Mild Cognitive Impairment (MCI) or not.

• 133 women completed 1 year of the trial and 128 completed 2 years.
• Prespecified covariates in all repeated measures analyses of covariance (RANCOVA) included age, education, APOE 4, and prior HT use.
• RANCOVA showed no overall significant treatment effects at year 1 or year 2.
• After testing for an interaction, which was significant (p = 0.02), we found that women in the HT group who scored at or above the average showed significantly less decline than the placebo group in short-delay verbal recall after 1 year, p = 0.007 and 2 years, p = 0.01.
• No treatment effects were found in women below the average in either year.
• When grouped according to whether the participant met criteria for MCI, the interaction between treatment group and MCI subgroup was not significant.

Today in Psychiatry...keeping you current

Receive free subspecialty "5-minute updates" via email

Estimation of clonazepam abuse liability: a new method using a reimbursed drug database
International Clinical Psychopharmacology, 10/20/09

Asenapine versus olanzapine in acute mania: a double-blind extension study
Bipolar Disorders, 10/22/09

Management of agitation and aggression associated with Alzheimers disease: controversies and possible solutions
Current Opinion in Psychiatry, 10/12/09

See All of Psychiatry